オプションチェーンは、Primech Holdingsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Primech Holdingsの市場センチメントを評価します。.

Primech Holdings (NASDAQ:PMEC) 株価情報, オプションチェーン

Primech Holdings

Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.

Movers

Trading Ideas

BIMI

DALN

FFIE

FGEN

GRPN

JTAI

LMND

MGNX

NUZE

PITA

PMEC

POWL

TBIO

TIVC

アドバンスト マイクロ デバイセズ社 (NASDAQ:AMD) の株は、予想を上回る第2四半期決算を受けて本日のプレマーケット取引で急騰している。

AMD株価上昇　決算を受けて

Primech Holdings Ltd

Qurate Retail, Inc. ("Qurate Retail" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRTEA#NASDAQ">QRTEA</a>, QRTEB, QRTEP))) announced that it received approval from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") to transfer the listing of the Company's Series A common stock ("QRTEA"), Series B common stock, and 8.0% Series A Cumulative Redeemable Preferred Stock (collectively, the "Securities") from the Nasdaq Global Select Market to the Nasdaq Capital Market. The listing of the Company's Securities was transferred to the Nasdaq Capital Market at the opening of business on December 2, 2024. This follows the notice received from Nasdaq on June 10, 2024 that, based on the closing bid price for QRTEA for 30 consecutive business days, Qurate Retail no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market (the "Minimum Bid Price Requirement").

News

QRTEA

Qurate Retail Transfers Equity Listing To The Nasdaq Capital Market

Dividends

TXNM

TXNM Energy Increases Annual Dividend From $1.55 to $1.63

WIIM

Campbell Soup shares are trading lower after the company reported Q1 sales that missed analyst estimates, despite better-than-expected adjusted EPS. Additionally, the company announced Mick Beekhuizen will succeed Mark Clouse as CEO, effective February 1, 2025.

<a href="http://www.xpo.com/">XPO</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>),&nbsp;a leading provider of freight transportation in North America,&nbsp;today reported certain preliminary LTL segment operating metrics for November 2024. LTL tonnage per day decreased 4.0%, as compared with November 2023, attributable to a year-over-year decrease of 4.2% in shipments per day and an increase of 0.2% in weight per shipment. Actual results for November 2024 may vary from the preliminary results reported above.

XPO Provides North American LTL Operating Data For November 2024; LTL Tonnage Per Day Decreased 4.0%, As Compared With November 2023, Attributable To A YoY Decrease Of 4.2% In Shipments Per Day And An Increase Of 0.2% In Weight Per Shipment

CURV

Torrid Holdings shares are trading lower after the company reported worse-then-expected Q3 financial results and issued Q4 and FY24 revenue guidance below estimates.

Featuring Analytics-Driven Augmented Viewing Experience Starting Dec. 10

GENI

TNT Sports Partners With NBA 2K And Genius Sports To Launch NBA 2K25 DataCast Telecast On truTV And Max For 2024 Emirates NBA Cup Knockout Round

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Global Affairs President Nick Clegg flagged the company&#8217;s evolving role in content moderation amid global elections, the latest of which was the <a target="_blank" href="https://about.fb.com/news/2024/12/2024-global-elections-meta-platforms/" rel="noreferrer noopener">U.S. presidential election</a>.
Clegg acknowledged the company&#8217;s responsibility as an operator of platforms where public exchange of views occurs amid elections in the world&#8217;s biggest democracies, including India, Indonesia, Mexico, and the European Union.&nbsp;&nbsp;
Previously, social media companies drew flak globally for spreading misinformation and content that perpetrated violence during elections.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42295863/apple-might-have-to-commit-1-billion-to-indonesia-to-reverse-iphone-16-ban" rel="noreferrer noopener">Apple Might Have To Commit $1 Billion To Indonesia To Reverse iPhone 16 Ban</a>
Facebook had suspended Donald Trump&#8217;s (then U.S. President) account from January 6, 2021, to January 7, 2023, following the Capitol Hill riot <a target="_blank" href="https://www.benzinga.com/news/21/06/21433780/facebook-suspends-trumps-accounts-for-2-years-former-president-calls-it-an-insult" rel="noreferrer noopener">in January 2021</a>. X, formerly&nbsp;known as Twitter, also banned Trump&#8217;s account after Facebook.
Therefore, Clegg acknowledged that the company had evolved its approach to elections since 2016 via trial and error, including forming a team of experts from its intelligence, data science, content and public policy, and legal teams.
In 2024, Meta ran multiple election operations centers globally amid primary elections, including the U.S., Bangladesh, Indonesia, India, Pakistan, and the EU Parliament.
Meta updated and applied its content policies throughout the year to help users freely communicate and exchange views.
Meta introduced political content controls on Facebook, Instagram, and Threads in the U.S. to recommend political content based on users&#8217; choices, the blog read. It is amid efforts to roll out the feature globally.&nbsp;
Meta permitted social media users to question or flag doubts about election processes, avoiding election-related speculation or bias that could promote violence.
For paid content, Meta&nbsp;barred&nbsp;ads that questioned the legitimacy of an election, something the company had done since 2020.
Meta revised its&nbsp;penalties system&nbsp;in 2023 to enable an effective exchange of views while punishing the policy violators. The company conducted annual audits of words it considered slurs under its Hate Speech policy.
Meta also&nbsp;revised its penalty protocol for public figures suspended for violations.
Clegg also acknowledged monitoring deepfakes and AI-enabled disinformation campaigns during the elections that helped combat potential threats from the misuse of generative AI.
Meanwhile, Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) chief and owner of X, Elon Musk, has actively promoted free speech and Trump during his <a target="_blank" href="https://www.benzinga.com/news/24/10/41353213/tesla-ceo-elon-musk-to-campaign-for-trump-in-pennsylvania-asks-attendees-to-support-free-speech-ther" rel="noreferrer noopener">2024 presidential campaigns</a>.
Meanwhile, Trump now expresses his views on Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) Truth Social, where he has <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/10/41333815/whats-going-on-with-trump-media-technology-group-stock-on-tuesday" rel="noreferrer noopener">a majority stake</a>.
Price Action: META stock closed higher by 3.61% at $613.65 on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42292183/citi-trends-q3-earnings-tops-estimates-margin-expansion-revises-guidance" target="_blank" rel="noreferrer noopener">Citi Trends Sales Beat Estimates With Margin Gains Despite Q3 Loss</a></li>
</ul>
Photo via Shutterstock

Tech

TSLA

Meta Platforms Talks Political Misinformation, Content Moderation In Latest Blog

Topline results demonstrated a statistically significant lower "Drug Liking" for the clinical doses of oral nalbuphine (81mg and 162mg) compared to 6mg IV butorphanol. The supratherapeutic dose of oral nalbuphine (486mg) was numerically lower than the 6mg IV butorphanol for "Drug Liking" but the results were not statistically significant.
Secondary endpoints included&nbsp;pharmacodynamic markers and patient reported outcomes, which were generally consistent with the primary endpoint. No serious adverse events were reported in the study.

TRVI

Trevi Therapeutics Reports Results From  Human Abuse Potential Study Of Oral Nalbuphine; Statistically Significant Lower 'Drug Liking' For 81Mg And 162Mg Doses Of Oral Nalbuphine Vs. Butorphanol Covering Clinical Dose Range

NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced completion of enrollment and implant procedures in its feasibility investigational device exemption (IDE) study of the RNS&#xAE; System for the treatment of Lennox-Gastaut Syndrome (LGS), a devastating form of childhood-onset epilepsy characterized by cognitive dysfunction and frequent generalized onset seizures that often lead to injury.
The IDE study uses the RNS System, which has demonstrated safety and effectiveness of brain-responsive stimulation for treating medically intractable focal onset seizures in people 18 and older, to evaluate whether brain-responsive neurostimulation can also be used to treat LGS.
NeuroPace received a $9.3 million National Institutes of Health (NIH) grant through the Brain Research through Advancing Innovative Neurotechnologies&#xAE; <a href="https://www.globenewswire.com/Tracker?data=w3qN0nEC75XJaIt7q6KRHCZ4H0uag9XxaWKGEZo6HH8AOctWZP3KjH72ghrvCHhLQq6ttLKNmiA1Eqc05sriPJRCNAJr-R38uNjkfeTyNMI=">(BRAIN) Initiative</a> to evaluate its responsive neuromodulation technology in those who suffer from LGS. The IDE study funded by the grant was conducted at six sites and enrolled a total of 20 patients 12 years of age and older with LGS and drug-resistant generalized onset seizures. The study will evaluate the safety and effectiveness of the RNS System in treating seizures associated with LGS.

Biotech

Contracts

General

NPCE

NeuroPace Completes Enrollment In Feasibility Study Of RNS System For Lennox-Gastaut Syndrome;  Received A $9.3M National Institutes Of Health Grant Through The Brain Research Through Advancing Innovative Neurotechnologies Initiative To Evaluate Its Responsive Neuromodulation Technology In Those Who Suffer From LGS

Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) reported its Q3 earnings results on Tuesday, December 3, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Torrid Holdings missed estimated earnings by -133.0%, reporting an EPS of $-0.01 versus an estimate of $0.03.
Revenue was down $11.64 million from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.
Here's a look at Torrid Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.08</td>
<td>0.07</td>
<td>-0.08</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>0.12</td>
<td>-0.04</td>
<td>-0.03</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>285.37M</td>
<td>282.40M</td>
<td>274.83M</td>
<td>245.83M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>284.64M</td>
<td>279.77M</td>
<td>293.54M</td>
<td>275.41M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Torrid Holdings <a href="https://www.benzinga.com/quote/CURV/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Torrid Holdings Earnings Analysis: Q3 Recap

Guidance

Torrid Holdings Sees Q4 Revenue $255M-$270M Vs $290.63M Est.

IREN Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) (ACN 629 842 799) ("IREN") today announced its intention to offer, subject to market and other conditions, $300&nbsp;million aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). IREN also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $45&nbsp;million principal amount of notes.
The notes will be senior, unsecured obligations of IREN, will accrue interest payable semi-annually in arrears and will mature on June 15, 2030, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. IREN will settle conversions by paying or delivering, as the case may be, cash, its ordinary shares or a combination of cash and its ordinary shares, at its election.

Offerings

IREN

IREN Announces Its Intention To Offer $300M Aggregate Principal Amount Of Convertible Senior Notes Due 2030

BASE

Couchbase shares are trading lower after the company issued Q4 revenue guidance below estimates.

Insider Trades

Goldman Sachs CEO David Solomon Sells 6,550 Shares For ~$4M At $610.91 Each, Retains 117,883 Shares Directly And 16,171 Indirectly Through Family Trust

Salesforce shares are trading higher after the company reported Q3 earnings and raised its guidance.

<a href="https://www.globenewswire.com/Tracker?data=8Tf7Z3_YTnk-drIFCyK3YwK5fBKtJERg8a5F3K8syiG68jnjCZnBJKIYCATZd01jimcmqpP1528lJYHqXWY-ma414azilZr-CI5Zg79wOZw=">Tectonic Therapeutic, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) ("Tectonic") a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, <a href="https://www.globenewswire.com/Tracker?data=0eWtnXxZi0DLMosegLjoiOoxfutWhH7qSlf7dqC2xfyHNQu-tfX-H-3N7YMQ4Mml7pdz18Wt2RW-5K2mAnTcbFd--zxV1VGeBPo_CnnN2LU=">click here</a>.
Key opinion leaders will include John R. Teerlink, MD, FHFSA (University of California San Francisco) and Raymond L. Benza, MD, FACC, FAHA, FACP (Icahn School of Medicine at Mount Sinai), who will discuss the unmet medical need and current treatment landscape for patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (Group 2 PH-HFpEF).
The event will focus on Tectonic's lead program, TX45, an investigational Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in patients with Group 2 PH-HFpEF in an ongoing Phase 1b hemodynamic proof-of-concept study and a Phase 2 clinical proof-of-concept study.
A live question and answer session will follow the formal presentations.

TECX

Tectonic Therapeutic To Host KOL Event On The Unmet Need In Group 2 PH-HFpEF And TX45 As A Potential Treatment On Thursday, December 12, 2024 From 4:00 PM To 6:00 PM ET

The partnership also includes the successful demonstration of Parsons' software-defined satellite communications solution using Globalstar's Low Earth Orbit (LEO) satellite constellation.

GSAT

Parsons, Globalstar Enter Exclusive Partnership To Support The Public, Government, And Defense Sectors

Torrid Holdings Sees FY24 Revenue $1.083B-$1.098B Vs $1.139B Est.

PSTG

Public Storage shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 guidance above estimates.

Salesforce Raises Full Year FY25 GAAP Operating Margin Guidance To 19.8% And Raises non-GAAP Operating Margin Guidance to 32.9%

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Macrogenics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mgnx-stock-quote/">MGNX</a>) stock is dropping on Wednesday as the biopharmaceutical company prepares to <a href="https://www.nasdaq.com/press-release/macrogenics-provides-vobramitamab-duocarmazine-update-2024-07-30">discontinue a clinical trial</a> of vobramitamab duocarmazine.



This is the company&rsquo;s candidate for metastatic castration-resistant prostate cancer (mCRPC). The company has decided to no longer move forward with its TAMARACK Phase 2 study for patients who could have received additional doses.



Macrogenics&nbsp;is making this decision due to the primary endpoint of its study already being met. This suggestion came from the Independent Data Monitoring Committee (IDMC) of the clinical trial. It will present this data in a poster presentation in September.



Scott Koenig, M.D., Ph.D., president and CEO of&nbsp;MacroGenics, said the following about the news.




&ldquo;Patient safety is our top priority, and having reached the study&rsquo;s primary endpoint, we decided to discontinue additional dosing for the remaining TAMARACK participants who had not yet completed treatment. We expect to have the data necessary to determine next steps for the vobra duo program later this year and will provide further updates on an investor call following our ESMO presentation.&rdquo;




<h2>How This Affects MGNX Stock</h2>



Investors aren&rsquo;t reacting well to this news with shares of MGNX stock falling 28.2% as of Wednesday morning. The stock was also down 48.3% year-to-date when markets closed on Tuesday.



Investors who are seeking out even more of the most recent stock market stories today are in the right place!



We have all of the hottest stock market happenings that traders need to read about on Wednesday! That includes everything happening with shares of FibroGen&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) stock, Nuzee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock and Primech&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pmec-stock-quote/">PMEC</a>) stock this morning. You can catch up on all of these matters by checking out the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-fibrogen-fgen-stock-down-44-today/">Why Is FibroGen (FGEN) Stock Down 44% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-64-today/">Why Is Nuzee (NUZE) Stock Up 64% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-primech-pmec-stock-up-60-today/">Why Is Primech (PMEC) Stock Up 60% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-macrogenics-mgnx-stock-down-28-today/">Why is Macrogenics (MGNX) Stock Down 28% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why is Macrogenics (MGNX) Stock Down 28% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
FibroGen&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) stock is falling hard on Wednesday after the biopharmaceutical company <a href="https://www.nasdaq.com/press-release/fibrogen-announces-topline-results-two-late-stage-pamrevlumab-pancreatic-cancer">reported results from failed clinical trials</a>.



The first failed clinical trial covers the treatment of metastatic pancreatic cancer with pamrevlumab. FibroGen&nbsp;said that this didn&rsquo;t meet its primary endpoint of overall survival. This was determined based on the protocol pre-specified Bayesian statistical analysis.



The second failed study covered the use of pamrevlumab&nbsp;combined with gemcitabine + nab-paclitaxel to treat unresectable pancreatic cancer. Yet again, the clinical trial failed to reach its primary endpoint of overall survival.



These are major blows to FibroGen&nbsp;as these weren&rsquo;t early clinical trials. The metastatic pancreatic cancer trial was in the Phase 2/3 range while the unresectable pancreatic cancer one was a Phase 3 study.



FibroGen&nbsp;CEO Thane Wettig said the following about the clinical trial results.




&ldquo;We are deeply disappointed that the pamrevlumab arm in the Precision Promise trial and the LAPIS trial did not meet the primary endpoint of overall survival. We were hopeful that pamrevlumab could bring meaningful innovation to pancreatic cancer patients in desperate need of new therapies.&rdquo;




<h2>What&rsquo;s Next for FGEN Stock</h2>



Considering the results of these clinical trials, FibroGen&nbsp;is immediately going to go into cost-saving mode. That includes the termination of the pamrevlumab program. This will reduce its total headcount by 75%.



FGEN stock is down 44.4% as of Wednesday morning.



Investors will want to stick around for more of the most recent stock market news!



We have all of the latest market happenings worth reading about today! A few examples include what&rsquo;s going on with shares of Nuzee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) and Primech&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pmec-stock-quote/">PMEC</a>) stock, as well as the biggest pre-market stock movers this morning. All of this info is ready to go at the links below!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-64-today/">Why Is Nuzee (NUZE) Stock Up 64% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-primech-pmec-stock-up-60-today/">Why Is Primech (PMEC) Stock Up 60% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-31st/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Wednesday</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-fibrogen-fgen-stock-down-44-today/">Why Is FibroGen (FGEN) Stock Down 44% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is FibroGen (FGEN) Stock Down 44% Today?

Primech Holdings Ltd. (PMEC) has released an update. At Primech Holdings Ltd.'s 2024 Annual Meeting, shareholders overwhelmingly approved the Direc...

Primech Holdings Shareholders Approve Key Resolutions

Primech AI, a subsidiary of Primech Holdings (PMEC), announces the launch of Hytron, an AI-powered automated toilet cleaning robot, now operational...

Primech AI launches AI-powered automated toilet cleaning robot

Primech and its subsidiary, Primech AI, announce new strategic partnerships with Unity Group Holdings International Limited, a provider of energy s...

Primech Holdings, Primtech AI enter strategic partnerships with Unity Group

Primech AI, a subsidiary of Primech Holdings (PMEC), unveiled its strategic expansion plans for HYTRON, its AI-powered public toilet cleaning robot...

Primech Holdings subsidiary unveils future plans

Primech Holdings (PMEC) announced that it received a letter from Nasdaq, notifying the company that it is eligible for an additional 180 calendar d...

Primech Holdings receives noncompliance notification from Nasdaq

Primech receives Nasdaq minimum bid price requirement extension

Primech Holdings Ltd. (PMEC) has released an update. Primech Holdings Ltd. has been granted an additional 180-day extension by Nasdaq to meet the m...

Primech Holdings Granted Nasdaq Extension to Meet Bid Price

10:38 EST Primech Holdings (PMEC) files $50M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving br...

Primech Holdings files $50M mixed securities shelf

Press Releases

Primech Holdings Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Primech Holdings Launches Primech Ai, the Creator of a Fully Autonomous, Ai-Powered Toilet-Cleaning Robot

Primech Holdings Reports 5.1% Increase in Revenue, $144.4 Million in Future Contracted Revenues Guidance

Primech Holdings Subsidiary Nominated as a Finalist for the Singapore Apex Corporate Sustainability Awards

Primech Secures Major New Contracts, Paving the Way for Future Growth

Primech AI, a Subsidiary of Primech Holdings, Launches AI-Powered Automated Toilet Cleaning Robot, Hytron

Primech Holdings and Primech AI Forge Strategic Partnerships with Unity Group for Advanced Energy and Robotics Solutions

Primech AI, a Subsidiary of Primech Holdings, Unveils Ambitious Future Plans for its Innovative Toilet Cleaning Robot, HYTRON

Primech Holdings Subsidiary Primech A&P Earns Leading Industry Awards for Excellence in Cleanliness and Hygiene

Primech Holdings Receives NASDAQ Minimum Bid Price Requirement Extension

ABM Indus

Ambipar Emergency Response Class A Ordinary Shares

Ambipar Emergency

Aris Water Solutions, Inc. Class A Common Stock

Aris Water Solutions

Mobile Infrastructure Corporation Common Stock

Mobile Infrastructure

BrightView Hldgs

CDT Environmental Technology Investment Holdings Limited - ordinary shares

CDT Environmental

CECO Environmental

Clean Harbors

Casella Waste Systems, Inc. - Class A Common Stock

Casella Waste Sys

ESGL Holdings Limited - Class A Ordinary Shares

ESGL Holdings

Fuel Tech

Li-Cycle Holdings

LanzaTech Global

Montrose Environmental Group, Inc. Common Stock

Montrose Environmental Gr

Enviri

Perma-Fix Environmental Services, Inc. - Common Stock

Perma-Fix Envirn Servs

Quest Resource Holding Corporation - Common Stock

Quest Resource Holding

Rollins

Republic Servs

Rentokil Initial plc American Depositary Shares (each representing five (5) Ordinary Shares)

Comments

Primech Holdings

Primech Holdings (PMEC) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル